Reference - Detail
| RRC ID | 62006 |
|---|---|
| Author | Inami K, Kajino K, Abe M, Hagiwara Y, Maeda M, Suyama M, Watanabe S, Hino O. |
| Title | Secretion of N-ERC/mesothelin and expression of C-ERC/mesothelin in human pancreatic ductal carcinoma. |
| Journal | Oncol Rep |
| Abstract |
ERC/mesothelin gene (MSLN) encodes a precursor protein, which is cleaved by proteases to generate N-ERC/mesothelin and C-ERC/mesothelin. N-ERC/mesothelin is a soluble protein, also known as megakaryocyte-potentiating factor, which is released into extracellular space. N-ERC/mesothelin is known to be a serum marker of mesothelioma. We have previously developed an enzyme-linked immunosorbent assay system for N-ERC/mesothelin, which can detect mesothelioma. C-ERC/mesothelin is expressed in normal mesothelial cell, pancreatic cancers, ovarian cancers, mesotheliomas and some other cancers. Pancreatic ductal carcinoma remains a fatal disease because its diagnosis often occurs very late. In this study, we examined ERC/mesothelin expression in human pancreatic cancer cell lines (MIA-PaCa2, PK-1, KP-3, TCC-PAN2, PK-59 and PK-45H) by reverse transcription-polymerase chain reaction and immunoblotting and N-ERC/mesothelin concentration in the supernatant of cultured cancer cells by the ELISA system. We also investigated C-ERC/mesothlein expression in human pancreatic ductal carcinoma tissues by immunostaining using 5B2 anti-mesothelin monoclonal antibody and N-ERC/mesothelin concentration in sera obtained from patients with pancreatic ductal carcinoma via ELISA. In vitro, N-ERC/mesothelin concentration in cell culture medium nearly correlated with the expression level of C-ERC/mesothelin. Although C-ERC/mesothelin was frequently expressed in human pancreatic ductal carcinoma, serum N-ERC/mesothelin concentration of cancer patients was equivalent to healthy controls. N-ERC/mesothelin was not useful as a serum marker of pancreatic ductal carcinoma, but because of frequent expression, C-ERC/mesothelin might be useful as a target of molecular imaging and immunotherapy. |
| Volume | 20(6) |
| Pages | 1375-80 |
| Published | 2008-12-1 |
| PMID | 19020717 |
| MeSH | Aged Antibodies, Monoclonal / chemistry Antigens, Neoplasm / metabolism Biomarkers, Tumor / metabolism Carcinoma, Pancreatic Ductal / metabolism* Cell Line, Tumor Enzyme-Linked Immunosorbent Assay GPI-Linked Proteins Gene Expression Gene Expression Regulation, Neoplastic* Humans Immunotherapy / methods Membrane Glycoproteins / biosynthesis* Membrane Glycoproteins / blood* Membrane Glycoproteins / metabolism* Mesothelin Middle Aged Pancreatic Neoplasms / metabolism* Reverse Transcriptase Polymerase Chain Reaction |
| IF | 3.417 |
| Altmetric score |
オルトメトリクス指標項目
|
| The most frequently cited source | Patent(IFI CLAIMS) |
| Total number of mentions | 12 |
| Altmetric score changes over past 6months | 6.0 |
| Resource | |
| Human and Animal Cells | PK-59(RCB1901) PK-45H(RCB1973) |